

South Carolina  
**Department of Health and Human Services**  
Post Office Box 8206  
Columbia, South Carolina 29202-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**November 4, 2020**  
**MINUTES**

**1. Call to Order**

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 4, 2020.

**2. Welcome**

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

**3. Committee Members Present:**

Divya Ahuja, MD  
Kimberly Rudd, MD  
Cheryl Hartvigsen, RPh  
Erika Tillery, PharmD

Edward Behling, MD  
Kenric Ware, PharmD  
Kelly Barth, MD  
Kashyap Patel, MD

Jony Bolinger, MD  
Phillip Mubarak, MD  
Gregory Browning, MD  
Duncan Norton, MD

**SC DHHS Staff:**

Jim Bradford, MD  
William Wynn, PharmD  
Janelle Smith  
Janet Giles  
Michael Psikogios, MD  
Ashley Sirianni, DNP, FNP-BC  
Nicole Wetherton, JD

**Magellan Medicaid Admin:**

Lisa Correll, PharmD  
Lori Ash

**4. Discussion Topics**

**A. Committee Meeting Minutes, Wednesday, August 5, 2020**

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

**B. Public Comment**

<b>Company</b>	<b>Speaker</b>	<b>Drug/Class</b>
Sanofi Genzyme	Manuel Nunez, PharmD	MS Agents
Biogen	Tanner Odom, PharmD	MS Agents
Novartis	Sharon Reizner, PharmD	MS Agents
Abbott	Marie Frazzitta, DNP, FNP-c, CDCES, MBA	CGM Monitors
Dexcom	Roy Thomas, PharmD	CGM Monitors

**C. Drug Classes for Review**

*Classes for Re-Review*

- Alzheimer’s Agents (cholinesterase inhibitors)
- Antihistamines, Minimally Sedating
- Hematopoietic Agents
- Macrolides and Ketolides
- Multiple Sclerosis Agents
- Continuous Blood Glucose Monitors (stand-alone)

The chart below represents the recommendations from the P & T Committee:

<b>ALZHEIMER’S AGENTS (Cholinesterase Inhibitors)</b>	
Preferred	Non-Preferred
Donepezil IR, ODT	Aricept
Exelon transdermal‡	Donepezil 23mg
Rivastigmine caps	Exelon caps
	Razadyne ER, Soln
	Rivastigmine transdermal generic/AG
<b>ANTIHISTAMINES, MINIMALLY SEDATING</b>	
Preferred	Non-Preferred
Cetirizine OTC tabs, caps, soln	Allegra
Fexofenadine OTC 60, 180mg and susp	Cetirizine chew tab and soln
Levocetirizine tabs and OTC‡	Claritin
Loratadine OTC, ODT and tabs	Clarinex
	Xyzal
	Zyrtec

<b>HEMATOPOIETIC AGENTS</b>	
Preferred	Non-Preferred
Epogen (rHuEPO)‡	Aranesp <sup>+</sup>
Retacrit (rHuEPO-epbx)‡	Procrit <sup>+</sup>
	Mircera <sup>+</sup>
	Reblozyl <sup>+</sup>
<b>MACROLIDES AND KETOLIDES</b>	
Preferred	Non-Preferred
Azithromycin tab, susp, pkt	Biaxin
Clarithromycin tab, susp	Biaxin XL
E.E.S. 200 Suspension‡	E.E.S 400 tab
EryPed 200, 400mg suspension‡	Ery-Tab <sup>+</sup>
	Erythromycin base <sup>+</sup>
	Erythromycin Ethylsuccinate <sup>+</sup>
	Ketek
	Zmax
	Zithromax
<b>MULTIPLE SCLEROSIS AGENTS</b>	
Preferred	Non-Preferred
Avonex	Copaxone 40mg/mL
Betaseron	Extavia
Copaxone 20mg/mL	Glatiramer
Tecfidera‡	Kesimpta
	Plegridy (pegylated)
	Rebif <sup>+</sup>
	Ampyra
	Aubagio
	Bafiertam
	Gilenya
	Mavenclad
	Mayzent
	Vumerity
	Zeposia
<b>CONTINUOUS BLOOD GLUCOSE MONITORS (“stand alone”)</b>	
Preferred	Non-Preferred
Dexcom G6	Medtronic
Freestyle Libre (14 day)	
Freestyle Libre2‡	

- ‡ Added as “Preferred”  
<sup>+</sup> Moved to “Non-Preferred”

**5. Old Business**  
None

**6. New Business**

Lisa presented new drugs to market. William updated the Committee that effective July 15, 2020, payment algorithm updated to include NADAC + \$10.50 dispensing fee. SC DHHS has developed AAC pricing with Mercer which will be implemented November 16, 2020. Additionally, William discussed COVID vaccine coverage and shared the dedicated COVID19 website. Current COVID covered items will remain in effect until January 20, 2021 unless extended.

**7. Resolved Items**

*Classes for Re-Review*

- Alzheimer's Agents (cholinesterase inhibitors)
- Antihistamines, Minimally Sedating
- Hematopoietic Agents
- Macrolides and Ketolides
- Multiple Sclerosis Agents
- Continuous Blood Glucose Monitors (stand-alone)

**8. Closing Comments**

The next meeting will be held Wednesday, February 3, 2021.

**9. Adjournment**

The meeting adjourned at 5:47 p.m.